NCT05343871View on ClinicalTrials.gov

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

2,354

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

July 28, 2023

Study Completion Date

January 11, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

Sinovac

"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"

BIOLOGICAL

AZD1222

"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"

BIOLOGICAL

BNT162b2

"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"

Trial Locations (2)

Unknown

FIOCRUZ, Campo Grande

Aga Khan University Clinical Trials Unit, Karachi

All Listed Sponsors
collaborator

Aga Khan University

OTHER

collaborator

Oswaldo Cruz Foundation

OTHER

collaborator

Stanford University

OTHER

lead

Albert B. Sabin Vaccine Institute

OTHER